PFS Nearly Doubles with Faridoxorubicin Treatment

Avacta's AVA6000 nearly doubles progression-free survival in salivary gland cancer trial subset.

What the company is saying

Avacta Group plc reports updated results from its ongoing Phase 1a/1b trial of faridoxorubicin (AVA6000) in salivary gland cancer, highlighting a median progression-free survival (PFS) of 11.4 months in a defined subset of 32 patients, compared to historical benchmarks of 6-6.7 months. The company emphasizes that this represents a near doubling of PFS, framing the data as evidence of the pre|CISION® platform’s ability to deliver potent payloads to tumors with sustained activity and reduced toxicity compared to antibody-drug conjugates. CEO Christina Coughlin positions the results as a validation of the platform’s durability and potential to improve cancer outcomes, while also referencing new preclinical findings on AVA6103, the next-generation candidate. The announcement stresses the durability of FAP expression and persistent drug release, supported by imaging and pharmacokinetic data. Avacta also notes that multiple partial and minor tumor responses were observed, and that the drug was well-tolerated in the analyzed group. The company is presenting these results at the ESMO Congress in Madrid, with Alan Ho, MD, PhD, from Memorial Sloan Kettering Cancer Center, serving as a senior author and providing external clinical endorsement.

What the data suggests

The disclosed data show a median PFS of 11.4 months (95% CI: 7 months, not reached) in a subset of 32 salivary gland cancer patients treated at doses of 310 mg/m2 and above, nearly double the historical benchmark of 6-6.7 months from published studies. The trial observed 3 partial and 6 minor responses, with response durations ranging from 18.7 to 72 weeks. Biopsy data revealed a tumor to plasma concentration ratio of released doxorubicin of 100:1, indicating effective tumor targeting even at low FAP expression (1+). FAPI-PET imaging and immunohistochemistry confirmed that FAP expression in tumors remained stable over time, even as tumors responded to therapy. Pharmacokinetic studies out to 12 cycles showed persistent FAP activity and stable drug cleavage. The total SGC enrollment was 51 patients, but the efficacy subset excluded those with rare histologies or extensive prior therapy. No median overall survival has been reached. The data cutoff was October 5, 2026. No quantitative safety or adverse event data are disclosed, and claims of tolerability are not numerically supported. The results are specific to the SGC subset, with data for soft tissue sarcoma and triple-negative breast cancer still maturing.

Analysis

The announcement presents detailed and specific clinical data from an ongoing Phase 1a/1b trial, including a median progression-free survival (PFS) of 11.4 months in a defined subset of salivary gland cancer patients, which is nearly double historical benchmarks. The majority of claims are realised and supported by disclosed numerical data (e.g., patient numbers, response rates, pharmacokinetic findings). However, some language is inflated, such as describing tumor shrinkage as 'meaningful' without quantitative thresholds, and stating the drug was 'well-tolerated' without safety data. The only forward-looking claim relates to future data presentations for AVA6103, which is a minor portion of the overall narrative. No large capital outlay or financial data is disclosed, and the benefits described are already being realised in the trial context. The gap between narrative and evidence is moderate, with most claims substantiated but some overstatement in qualitative descriptors.

Risk flags

• ●The efficacy results are limited to a subset of 32 patients with salivary gland cancer, excluding those with rare histologies or extensive prior therapy, which may limit generalizability to the broader patient population. This selection bias could inflate apparent benefit compared to real-world outcomes.
• ●No quantitative safety or adverse event data are provided, so the claim of good tolerability cannot be independently verified. Without detailed safety data, the risk of unexpected toxicity or adverse effects remains unquantified.
• ●Median overall survival has not been reached, so long-term benefit and impact on survival remain unknown. This creates uncertainty about the ultimate clinical value of AVA6000.
• ●Data for other indications (soft tissue sarcoma and triple-negative breast cancer) are still maturing, so the platform’s broader applicability and commercial potential are not yet established.
• ●The trial remains in early-phase development, and regulatory approval will require larger, controlled studies. There is significant execution risk in advancing from promising early results to registrational trials and eventual commercialization.

Bottom line

Avacta’s updated Phase 1a/1b trial results for AVA6000 in salivary gland cancer show a median progression-free survival of 11.4 months in a selected subset, nearly double historical benchmarks, with multiple partial and minor tumor responses and evidence of durable drug activity. The data are robust for this subset but exclude patients with rare histologies or extensive prior therapy, which may limit applicability. No quantitative safety data are disclosed, so the risk profile is unclear despite claims of tolerability. The results are a positive signal for the pre|CISION® platform’s tumor-targeting approach, but broader efficacy, safety, and survival data—as well as results in other cancer types—are still pending. Investors should watch for upcoming AVA6103 data in late 2026 and first efficacy readouts in H1 2027. The key takeaway is that AVA6000 shows strong early efficacy signals in a defined group, but the path to regulatory approval and commercial impact remains long and uncertain.

Announcement summary

(AIM:AVCT) Avacta Group plc announced updated data from its ongoing Phase 1a/1b trial of faridoxorubicin (AVA6000) in patients with salivary gland cancer (SGC), reporting a median progression-free survival (PFS) of 11.4 months in a defined subset of patients, compared to published historical benchmarks of 6-6.7 months. The SGC efficacy subset included 32 patients treated at doses of 310 mg/m2 and above, with rare histologies and those with more extensive prior therapy excluded from this analysis. The 11.4 month median PFS (95% confidence interval: 7 months, not reached) represents a near doubling compared to historical benchmarks. Meaningful tumor shrinkage was observed in the patient population, with multiple partial (n=3) and minor responses (n=6) recorded, and response durations ranging from 18.7 to 72 weeks. Biopsy data showed a tumor to plasma concentration ratio of released doxorubicin of 100:1, resulting in tumor reductions even at low FAP expression (1+). FAPI-PET imaging and FAP IHC data indicated that FAP expression in tumors does not diminish over time during treatment, even in the setting of tumor response. Plasma pharmacokinetic studies out to 12 cycles of therapy demonstrated stable cleavage of faridoxorubicin to peptide and doxorubicin by FAP, indicating persistent FAP activity in tumors. AVA6000 is administered as an infusion every three weeks (Q3W) or every two weeks (Q2W). A total of 51 patients with SGC were enrolled across all doses and cohorts, with any prior therapy. The data cutoff for this analysis was October 5, 2026. The Phase 1a dose escalation enrolled patients with cancers frequently noted as FAP-positive, and three indications were selected for Phase 1b expansion: SGC, soft tissue sarcoma (STS), and triple-negative breast cancer (TNBC), with data sets for STS and TNBC continuing to mature. The endpoints include safety, pharmacokinetics, and preliminary efficacy. Data from the trial in patients with FAP-positive solid tumors were presented at the European Society for Medical Oncology (ESMO) Congress in Madrid, held between 23-27 October 2026. Christina Coughlin, CEO of Avacta, stated that the pre|CISION® platform is capable of delivering highly potent payloads to tumors over prolonged periods with sustained antitumor activity and without the toxicity that limits the effectiveness of antibody-drug conjugates (ADCs). New preclinical data presented at ESMO on FAP-Exd (AVA6103), Avacta’s first Next-Generation pre|CISION® controlled-release PDC, demonstrated that treated tumors recruit new FAP+ fibroblasts, enhancing the capacity of the tumor to continue to cleave the pre|CISION medicines over time. Alan Ho, MD, PhD, Chief, Head and Neck Oncology Service, Memorial Sloan Kettering Cancer Center, New York, and Senior Author of the ESMO Presentation, commented that these are promising results with faridoxorubicin in patients with salivary gland cancers, highlighted by evidence of disease control in this rare set of diseases. The ESMO poster presentation was titled 'A Phase 1a/1b trial of FAP-Dox (AVA6000), a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with salivary gland cancers', authored by Renata Ferrarotto, Robert Metcalf, Steph A. Pang, William D. Tap, et al., and Alan L. Ho, with poster number 1549P, presented on Monday October 26, 12:00-12:45pm CET. Dr. Ho has financial interests related to Avacta Therapeutics. AVA6103 is being evaluated in the FOCUS-01 Phase 1 trial (FAP-Exd in Oncologic Cancers with Unmet needS).

Disagree with this article?